Lipigo F 10 Tablet is a combination lipid-lowering agent containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting cholesterol synthesis in the liver and increasing LDL receptor expression. The synergistic effect of these two agents provides comprehensive lipid control by significantly reducing triglycerides, LDL-C, and increasing high-density lipoprotein cholesterol (HDL-C). Lipigo F 10 is prescribed for patients who require additional lipid lowering beyond monotherapy or who have mixed dyslipidemia not adequately controlled by diet and exercise alone. It is essential to monitor liver function tests, renal function, and lipid profiles periodically during therapy. Caution is advised in patients with hepatic or renal impairment, and concomitant use with other lipid-lowering drugs should be carefully evaluated to minimize the risk of adverse effects such as myopathy or rhabdomyolysis. Patient adherence to lifestyle modifications remains critical for optimal therapeutic outcomes.